Company Encyclopedia
View More
name
Fudan-Zhangjiang
688505.SH
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer. In addition, it offers Osmotic pump technology platform drugs, which includes controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson’s disease; and Obeticholic acid for the treatment of hepatobiliary/autoimmune diseases.
3.196 T
688505.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking110/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-2.72%D
    • Profit Margin-8.81%D
    • Gross Margin90.78%A
  • Growth ScoreD
    • Revenue YoY2.89%C
    • Net Profit YoY-159.57%E
    • Total Assets YoY-6.14%D
    • Net Assets YoY-3.99%D
  • Cash ScoreD
    • Cash Flow Margin-1135.50%E
    • OCF YoY2.89%C
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreA
    • Gearing Ratio8.40%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fudan-Zhangjiang shareholder Yang Zongmeng plans to reduce holdings by no more than 10.37 million shares, accounting for no more than 1% of the equity

    Fudan-Zhangjiang shareholder Yang Zongmeng plans to reduce his holdings by no more than 10.3657 million shares through centralized bidding from November 26 to February 25 next year, with a reduction ratio not exceeding 1%. He promised that the reduction price would not be lower than the initial listing price, and the current adjusted amount per share is RMB 8.64. Yang Zongmeng is reducing his holdings due to funding needs and currently holds 6.18% equity

    etnet·
    SH
    688505
    -0.67%
    HK
    01349
    -2.42%
    etnet·
    SH
    688505
    -0.67%
    HK
    01349
    -2.42%

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Announces Extraordinary General Meeting for Strategic Amendments

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Announces Extraordinary General Meeting for Strategic Amendments

    Tip Ranks·
    HK
    01349
    -2.42%
    SH
    688505
    -0.67%
    Tip Ranks·
    HK
    01349
    -2.42%
    SH
    688505
    -0.67%

    Shareholders to Vote on Change in Use of IPO Proceeds at Next Shanghai Fudan-Zhangjiang Bio-Pharmaceutical EGM

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. will hold an extraordinary general meeting to vote on a proposal to change the use of proceeds from its A share IPO. The proposal seeks to reallocate unused funds to a new project, extending the utilization timeline to December 31, 2027. The board recommends voting in favor of this proposal.

    Reuters·
    HK
    01349
    -2.42%
    SH
    688505
    -0.67%
    Reuters·
    HK
    01349
    -2.42%
    SH
    688505
    -0.67%

    "Performance" Fudan-Zhangjiang reported a loss of 15.94 million RMB in the first three quarters, turning from profit to loss

    Fudan-Zhangjiang announced its third-quarter report for the period ending in September, achieving operating revenue of 551 million RMB (same below) according to Chinese accounting standards, a slight increase of 0.4% year-on-year. The net loss was 15.94 million RMB, compared to a net profit of 86.47 million RMB in the same period last year, turning from profit to loss; the loss per share was 0.02 RMB

    AASTOCKS·
    SH
    688505
    -0.67%
    HK
    01349
    -2.42%
    AASTOCKS·
    SH
    688505
    -0.67%
    HK
    01349
    -2.42%

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Proposes Governance Amendments

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. (HK:1349) has proposed amendments to its Articles of Association, pending shareholder approval at an extraordinary general meeting. The key change involves dissolving the supervisory committee, transferring its responsibilities to the audit committee, indicating a strategic shift in corporate governance. This move aims to enhance operational oversight and regulatory compliance in the biopharmaceutical sector, where the company focuses on innovative drug development within the Chinese market. Current market cap stands at HK$1.09B with an average trading volume of 6,837,274 shares.

    Tip Ranks·
    HK
    01349
    -2.42%
    SH
    688505
    -0.67%
    Tip Ranks·
    HK
    01349
    -2.42%
    SH
    688505
    -0.67%